On November 9, 2016, Alexion revealed that its top drug, Soliris, is being investigated for improper sales practices. Soliris is also estimated to account for 92% of Alexion's 2016 sales. Alexion also retained independent counsel and said it would be delaying its third-quarter financial report.
If you are aware of any facts relating to this investigation, or purchased Alexion shares, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/alxn. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-alexion-pharmaceuticals-inc-alxn-300360820.html
SOURCE Bronstein, Gewirtz & Grossman, LLC